Cargando…

Bimodal Expansion of the Lymphatic Vessels Is Regulated by the Sequential Expression of IL-7 and Lymphotoxin α(1)β(2) in Newly Formed Tertiary Lymphoid Structures

Lymphangiogenesis associated with tertiary lymphoid structure (TLS) has been reported in numerous studies. However, the kinetics and dynamic changes occurring to the lymphatic vascular network during TLS development have not been studied. Using a viral-induced, resolving model of TLS formation in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Nayar, Saba, Campos, Joana, Chung, Ming May, Navarro-Núñez, Leyre, Chachlani, Menka, Steinthal, Nathalie, Gardner, David H., Rankin, Philip, Cloake, Thomas, Caamaño, Jorge H., McGettrick, Helen M., Watson, Steve P., Luther, Sanjiv, Buckley, Christopher D., Barone, Francesca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AAI 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4991245/
https://www.ncbi.nlm.nih.gov/pubmed/27474071
http://dx.doi.org/10.4049/jimmunol.1500686
Descripción
Sumario:Lymphangiogenesis associated with tertiary lymphoid structure (TLS) has been reported in numerous studies. However, the kinetics and dynamic changes occurring to the lymphatic vascular network during TLS development have not been studied. Using a viral-induced, resolving model of TLS formation in the salivary glands of adult mice we demonstrate that the expansion of the lymphatic vascular network is tightly regulated. Lymphatic vessel expansion occurs in two distinct phases. The first wave of expansion is dependent on IL-7. The second phase, responsible for leukocyte exit from the glands, is regulated by lymphotoxin (LT)βR signaling. These findings, while highlighting the tight regulation of the lymphatic response to inflammation, suggest that targeting the LTα(1)β(2)/LTβR pathway in TLS-associated pathologies might impair a natural proresolving mechanism for lymphocyte exit from the tissues and account for the failure of therapeutic strategies that target these molecules in diseases such as rheumatoid arthritis.